Flow diagram of the population selection after a universal offer for early infant HIV diagnosis (N = 3013).

<p>Flow diagram of the population selection after a universal offer for early infant HIV diagnosis (N = 3013).</p

Correlates of adequate parental acceptance (n = 2962) of infant HIV testing (logistic regression).

<p>PEDITEST ANRS 12165 Study, Abidjan, Côte d'Ivoire, 2008.</p><p>OR: Odds Ratio; aOR: Adjusted Odds Ratio. NI: Not included.</p

Rate of maternal acceptance and adequate parental acceptance for routine early infant HIV testing (N = 3013).

<p>Rate of maternal acceptance and adequate parental acceptance for routine early infant HIV testing (N = 3013).</p

Correlates of maternal acceptance (n = 2962) of infant HIV testing (logistic regression).

<p>PEDITEST ANRS 12165 Study, Abidjan, Côte d'Ivoire, 2008.</p><p>OR: Odds Ratio; aOR: Adjusted Odds Ratio. NI: not included.</p

Additional file 1: of Estimating mother-to-child HIV transmission rates in Cameroon in 2011: a computer simulation approach

Methods of calculation of mother-to-child transmission probabilities and live births rate among HIV positive women. This additional file is a .docx file which contains description of mathematical models used to estimate mother-to-child transmission probabilities. It is also described here how live births rate among HIV positive women were calculated. (DOCX 37 kb

Two-Year Probability of Remaining Free from Severe Events (Hospitalization or Death) According to the Feeding Group and Pediatric HIV Status

<p>ANRS 1201/1202 Ditrame Plus study, Abidjan, Côte d'Ivoire, 2001–2005 (<i>n</i> = 557).</p

Two-Year Probability of Remaining Free from Validated Morbidity (Diarrhea, Acute Respiratory Infection, or Malnutrition) According to the Feeding Group and Pediatric HIV Status

<p>ANRS 1201/1202 Ditrame Plus Study, Abidjan, Côte d'Ivoire, 2001–2005 (<i>n</i> = 557).</p

Two-Year Probability of Remaining Free from Adverse Health Outcome (Hospitalization or Death or Validated Morbidity) According to the Feeding Group and Pediatric HIV Status

<p>ANRS 1201/1202 Ditrame Plus study, Abidjan, Côte d'Ivoire, 2001–2005 (<i>n</i> = 557).</p

Number of infants linked to ART after false-positive diagnosis, per 1,000 ART initiations, by assay specificity and MTCT risk.

<p>Multivariate sensitivity analysis varying specificity of the NAAT and infant HIV prevalence modelled by increasing MTCT risk. The vertical axis shows the number of infants with false-positive diagnosis initiating ART, per 1,000 ART initiations. Groups of coloured bars indicate 3 values for infant HIV prevalence at weaning (12 months of age): purple indicates a low MTCT risk scenario, with 12-month risk of 1.3%; green indicates the base-case value of 4.9%; and blue indicates a high MTCT risk scenario, with risk of 9.6%. Three values of NAAT specificity are shown within each MTCT risk scenario. For each combination of MTCT risk and NAAT specificity, bars indicate those who are truly HIV-uninfected (false-positive diagnosis). The left, dark-coloured bar in each pair reflects the outcome without confirmatory testing, and the right, light-coloured bar reflects the outcome with confirmatory testing. ART, antiretroviral therapy; EID, early infant diagnosis; MTCT, mother-to-child transmission; NAAT, nucleic acid amplification test.</p

Univariate sensitivity analyses examining the impact of variation in individual input parameters on the difference in cost per HIV-exposed infant between the without and with confirmatory testing strategies.

<p>Key parameters varied in sensitivity analyses are shown on the left. Values in parentheses indicate the range examined (from the value leading to the lowest difference in cost to the value leading to the greatest difference, with base-case values after the semicolon). The horizontal axis shows the difference in cost between the 2 strategies: without confirmatory testing minus with confirmatory testing. The bounds of the blue bar indicate the cost differences at the extreme parameter values; longer bars therefore indicate parameters to which the model results were more sensitive. Where confidence intervals were available for the primary data estimates used in the base case, we indicate the bounds of these confidence intervals with brackets overlying the blue bars; the distance between brackets therefore indicates the degree to which the base-case estimates are affected by parameter uncertainty. The blue bar reaches the far left axis (indicating a cost difference of 0) at the threshold value for each parameter where confirmatory testing is no longer cost-saving compared to without confirmatory testing. The grey vertical line indicates the value for each parameter at the base-case result: a savings of US$40 per infant with confirmatory testing. ART, antiretroviral therapy; EID, early infant diagnosis; NAAT, nucleic acid amplification test.</p